KR20070085227A - 합성 초글리코실화, 프로테아제 저항성 폴리펩티드 변이체,경구 제제 및 이를 이용한 방법 - Google Patents

합성 초글리코실화, 프로테아제 저항성 폴리펩티드 변이체,경구 제제 및 이를 이용한 방법 Download PDF

Info

Publication number
KR20070085227A
KR20070085227A KR1020077005432A KR20077005432A KR20070085227A KR 20070085227 A KR20070085227 A KR 20070085227A KR 1020077005432 A KR1020077005432 A KR 1020077005432A KR 20077005432 A KR20077005432 A KR 20077005432A KR 20070085227 A KR20070085227 A KR 20070085227A
Authority
KR
South Korea
Prior art keywords
polypeptide
protease resistant
ifn
amino acid
protease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020077005432A
Other languages
English (en)
Korean (ko)
Inventor
진 홍
스코트 디. 세이워트
로렌스 엠. 블라트
Original Assignee
앨리오스 바이오파마 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 앨리오스 바이오파마 인크. filed Critical 앨리오스 바이오파마 인크.
Publication of KR20070085227A publication Critical patent/KR20070085227A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020077005432A 2004-08-09 2005-08-08 합성 초글리코실화, 프로테아제 저항성 폴리펩티드 변이체,경구 제제 및 이를 이용한 방법 Withdrawn KR20070085227A (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US60013404P 2004-08-09 2004-08-09
US60020204P 2004-08-09 2004-08-09
US60/600,202 2004-08-09
US60/600,134 2004-08-09
US60441504P 2004-08-24 2004-08-24
US60428004P 2004-08-24 2004-08-24
US60/604,415 2004-08-24
US60/604,280 2004-08-24

Publications (1)

Publication Number Publication Date
KR20070085227A true KR20070085227A (ko) 2007-08-27

Family

ID=35908080

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077005432A Withdrawn KR20070085227A (ko) 2004-08-09 2005-08-08 합성 초글리코실화, 프로테아제 저항성 폴리펩티드 변이체,경구 제제 및 이를 이용한 방법

Country Status (9)

Country Link
US (2) US20060182716A1 (enExample)
EP (1) EP1789074A4 (enExample)
JP (1) JP2008513356A (enExample)
KR (1) KR20070085227A (enExample)
AU (1) AU2005273968A1 (enExample)
CA (1) CA2576030A1 (enExample)
IL (1) IL181083A0 (enExample)
MX (1) MX2007001589A (enExample)
WO (1) WO2006020580A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101432714B1 (ko) * 2014-02-21 2014-08-25 순천향대학교 산학협력단 벤조안트라센 오염 검출을 위한 마커 및 키트

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022593A2 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
AU2005269265B2 (en) * 2004-08-02 2012-01-12 Zenyth Operations Pty Ltd A method of treating cancer comprising a VEGF-B antagonist
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP1877434A2 (en) * 2005-05-04 2008-01-16 Nautilus Biotech Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
EP1909822B1 (en) * 2005-06-29 2013-09-25 Yeda Research And Development Co., Ltd. Recombinant interferon alpha 2 (ifn alpha 2) mutants
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
TW200804416A (en) 2006-06-19 2008-01-16 Nautilus Technology Llc Modified coagulation factor IX polypeptides and use thereof for treatment
AR078117A1 (es) 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
CN104645328A (zh) * 2006-10-03 2015-05-27 建新公司 TGF-β拮抗物治疗具有罹患支气管肺发育不良风险的婴儿的用途
US7802280B2 (en) 2007-04-03 2010-09-21 Google Inc. Approving transcoded advertisements in advertisement front end
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
PT2910570T (pt) 2008-03-18 2017-01-24 Novo Nordisk As Análogos de insulina acilados, estabilizados contra proteases
CN102159250B (zh) 2008-08-11 2014-08-06 尼克塔治疗公司 多臂的聚合烷酸酯偶联物
US9410891B2 (en) 2010-02-19 2016-08-09 Pacific Biosciences Of California, Inc. Optics collection and detection system and method
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
CN109134642A (zh) 2011-10-01 2019-01-04 株式会社糖锁工学研究所 加成糖链的多肽及含有该多肽的医药组合物
WO2013059885A2 (en) * 2011-10-28 2013-05-02 Cephalon Australia Pty Ltd Polypeptide constructs and uses thereof
EP3799880A3 (en) * 2012-03-03 2021-06-23 ImmunGene, Inc. Engineered antibody-interferon mutant fusion molecules
BR112014025132A2 (pt) 2012-04-11 2017-07-11 Novo Nordisk As formulações de insulina
US10053499B2 (en) 2013-03-29 2018-08-21 Glytech, Inc. Polypeptide having sialylated sugar chains attached thereto
WO2015148512A1 (en) 2014-03-24 2015-10-01 Qt Holdings Corp Shaped articles including hydrogels and methods of manufacture and use thereof
US9790467B2 (en) * 2015-09-22 2017-10-17 Qt Holdings Corp Methods and compositions for activation or expansion of T lymphocytes
PT3554534T (pt) 2016-12-16 2021-11-05 Novo Nordisk As Composições farmacêuticas contendo insulina
CA3071534A1 (en) * 2017-08-02 2019-02-07 Northwestern University Substituted fused pyrimidine compounds and uses thereof
CN112616315A (zh) * 2018-03-29 2021-04-06 赫尔辛基大学 C末端的cdnf和manf片段、包含它们的药物组合物及其用途
AU2019276776B2 (en) * 2018-06-01 2025-12-11 ILC Therapeutics Limited Compositions and methods relating to the treatment of diseases
BR112022002962A2 (pt) * 2019-08-16 2022-07-05 Applied Molecular Transport Inc Composições, formulações e produção e purificação de interleucina
AR117715A1 (es) * 2019-12-17 2021-08-25 Univ Nacional Del Litoral Unl Interferón hiperglicosilado con inmunogenicidad reducida
EP3901168A1 (en) * 2020-04-21 2021-10-27 Universität Duisburg-Essen Interferon alpha 2 variants and uses thereof

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3720760A (en) * 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
DE2031216A1 (de) * 1969-06-19 1971-01-14 Citizen Watch Co Ltd , Tokio Tag und Datum Stellvorrichtung fur Uhren mit Kalender
US3940475A (en) * 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
CA1049411A (en) * 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
USRE30985E (en) * 1978-01-01 1982-06-29 Serum-free cell culture media
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4657866A (en) * 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) * 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4737456A (en) * 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4927762A (en) * 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4810804A (en) * 1987-03-26 1989-03-07 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a heterobicyclic group having retinoid-like activity
EP0407401B1 (en) * 1988-02-26 1993-04-21 Genentech, Inc. Human relaxin formulation
US5270198A (en) * 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5240848A (en) * 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
DE69024261T2 (de) * 1989-05-24 1996-07-18 Merck & Co Inc Reinigung und Charakterisierung eines von einem Glioma abstammenden Wachstumsfaktors
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5518729A (en) * 1989-11-22 1996-05-21 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5716632A (en) * 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5310562A (en) * 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5726152A (en) * 1990-09-21 1998-03-10 Merck & Co., Inc. Vascular endothelial cell growth factor II
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
TW197439B (enExample) * 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
US5736371A (en) * 1991-06-04 1998-04-07 A Et S Biovecteurs Biodegradable particulate vector for transporting molecules having biological activity
US5283253A (en) * 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
US5200534A (en) * 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US5686268A (en) * 1992-06-19 1997-11-11 Pfizer Inc. Fused proteins
US5294637A (en) * 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) * 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
CA2141602A1 (en) * 1992-08-26 1994-03-03 Philip Leder Use of the cytokine ip-10 as an anti-tumor agent
FR2696458B1 (fr) * 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
US6214542B1 (en) * 1992-10-20 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services Quantification of indicators of fibrosis
US5279949A (en) * 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
WO1995000645A2 (en) * 1993-06-21 1995-01-05 Genentech, Inc. Process for producing relaxin
JP3220331B2 (ja) * 1993-07-20 2001-10-22 エチコン・インコーポレーテツド 非経口投与用の吸収性液体コポリマー類
US5728377A (en) * 1993-07-20 1998-03-17 Board Of Regents, The University Of Texas System Methods and compositions incorporating IP-10
US5426098A (en) * 1993-09-02 1995-06-20 Celtrix Pharmaceuticals, Inc. Increase in hematopoietic progenitor cells in peripheral blood by transforming growth factor beta
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
EP0662515B1 (en) * 1993-12-10 2000-11-15 Korea Institute Of Science And Technology Signal sequences for secretion of heterologous proteins from yeast
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US5536249A (en) * 1994-03-09 1996-07-16 Visionary Medical Products, Inc. Pen-type injector with a microprocessor and blood characteristic monitor
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5484720A (en) * 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5770383A (en) * 1994-12-30 1998-06-23 Ligand Pharmaceuticals, Inc. Tricyclic retinoids, methods for their production and use
US5770382A (en) * 1994-12-30 1998-06-23 Ligand Pharmaceuticals, Inc. Tricyclic retinoids, methods for their production and use
US5770378A (en) * 1994-12-30 1998-06-23 Ligand Pharmaceuticals, Inc. Tricyclic retinoids, methods for their production and use
US6090822A (en) * 1995-03-03 2000-07-18 Margolin; Solomon B. Treatment of cytokine growth factor caused disorders
US5811395A (en) * 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US6066318A (en) * 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
DE69736860T2 (de) * 1996-09-24 2007-05-16 Merck & Co., Inc. Verbindungen zur hemmung der angiogenese durch gentherapie
IL129326A0 (en) * 1996-10-09 2000-02-17 Boehringer Mannheim Pharm Corp Method for inhibiting stress-activated protein kinases
SI20024A (sl) * 1996-10-16 2000-02-29 Icn Pharmaceuticals, Inc. Purinovi L-nukleozidi, analogi in uporaba od teh
CN1133649C (zh) * 1996-10-18 2004-01-07 沃泰克斯药物股份有限公司 丝氨酸蛋白酶、特别是丙型肝炎病毒ns3蛋白酶的抑制剂
ZA984697B (en) * 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
TW517055B (en) * 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
GEP20022707B (en) * 1997-07-18 2002-06-25 Infimed Inc Us Biodegrading Macromers for the Controlled Release of Biologically Active Substances
US6168784B1 (en) * 1997-09-03 2001-01-02 Gryphon Sciences N-terminal modifications of RANTES and methods of use
JP2001526033A (ja) * 1997-12-08 2001-12-18 ジェネンテク・インコーポレイテッド ヒトインターフェロン−イプシロンというｉ型インターフェロン
ZA9811070B (en) * 1997-12-08 2000-07-03 Genentech Inc Type I interferons.
AR014621A1 (es) * 1997-12-12 2001-03-28 Macromed Inc Un poli (etilenglicol) con forma de estrella, heterofuncional, biocompatible, metodo para su obtencion y metodo para conjugarlo con una proteina
US6387879B1 (en) * 1997-12-15 2002-05-14 Dgi Biotechnologies, Inc. Compounds that bind growth to hormone receptor
US6423695B1 (en) * 1998-01-13 2002-07-23 Ribapharm, Inc. Cytokine related treatments of disease
EP1051157B1 (en) * 1998-01-30 2002-01-02 Scios Inc. Controlled release delivery of peptide or protein
US5961495A (en) * 1998-02-20 1999-10-05 Becton, Dickinson And Company Medication delivery pen having a priming mechanism
US6221053B1 (en) * 1998-02-20 2001-04-24 Becton, Dickinson And Company Multi-featured medication delivery pen
US6248095B1 (en) * 1998-02-23 2001-06-19 Becton, Dickinson And Company Low-cost medication delivery pen
WO1999061437A1 (en) * 1998-05-22 1999-12-02 Smithkline Beecham Corporation Novel 2-alkyl substituted imidazole compounds
US6685933B1 (en) * 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
IT1303736B1 (it) * 1998-11-11 2001-02-23 San Raffaele Centro Fond Peptidi derivati da rantes con attivita' anti-hiv.
EP1016414B1 (en) * 1998-12-17 2004-09-08 Applied Research Systems ARS Holding N.V. Human growth hormone to stimulate hematopoiesis and immune reconstitution after hematopoietic stem cell transplantation in humans
US6703225B1 (en) * 1999-01-12 2004-03-09 Sumitomo Pharmaceuticals Company, Limited Interferon-α
MXPA01010208A (es) * 1999-04-09 2003-07-21 Johnson & Johnson Composiciones farmaceuticas de eritropoyetina.
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US20040002474A1 (en) * 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
US6346269B1 (en) * 2000-05-08 2002-02-12 Standard Chem. & Pharm. Co., Ltd. Method for preparing an oral formulation containing acid-sensitive drugs and oral formulation made thereby
EP1712239A3 (en) * 2000-05-12 2007-08-22 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
US6673580B2 (en) * 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US6958388B2 (en) * 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
PL366705A1 (en) * 2001-04-06 2005-02-07 Maxygen Holdings Ltd. Interferon gamma polypeptide variants
AU2002338286A1 (en) * 2001-04-10 2002-10-28 Leo Pharma A/S Novel aminophenyl ketone derivatives
US6585398B1 (en) * 2001-06-22 2003-07-01 Genlyte Thomas Group, Llc Post top deck light fixture
JP2005519946A (ja) * 2002-03-12 2005-07-07 マキシジェン エーピーエス 発作の処置のためのインターフェロンβ様分子
KR20040020817A (ko) * 2002-08-31 2004-03-09 씨제이 주식회사 당쇄화된 사람 인터페론 알파 동종체
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
KR100781666B1 (ko) * 2004-11-02 2007-12-03 신영기 인간 인터페론-베타 변이체

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101432714B1 (ko) * 2014-02-21 2014-08-25 순천향대학교 산학협력단 벤조안트라센 오염 검출을 위한 마커 및 키트

Also Published As

Publication number Publication date
WO2006020580A2 (en) 2006-02-23
US20100099851A1 (en) 2010-04-22
AU2005273968A2 (en) 2006-02-23
CA2576030A1 (en) 2006-02-23
AU2005273968A1 (en) 2006-02-23
IL181083A0 (en) 2007-07-04
JP2008513356A (ja) 2008-05-01
WO2006020580A3 (en) 2006-12-07
MX2007001589A (es) 2007-08-02
US20060182716A1 (en) 2006-08-17
EP1789074A2 (en) 2007-05-30
EP1789074A4 (en) 2009-08-12

Similar Documents

Publication Publication Date Title
US7597884B2 (en) Hyperglycosylated polypeptide variants and methods of use
KR20070085227A (ko) 합성 초글리코실화, 프로테아제 저항성 폴리펩티드 변이체,경구 제제 및 이를 이용한 방법
US7407973B2 (en) Use of pirfenidone in therapeutic regimens
TWI375679B (en) Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
JP2011172572A (ja) 合成ケモカイン受容体リガンドおよびその使用方法
CN102712644A (zh) 丙肝病毒复制的新型大环抑制剂
US20070258946A1 (en) Combination Therapy for Treating Hepatitis C Virus Infection
JP2002543144A (ja) ＰＥＧ化インターフェロンαＣＣＲ５アンタゴニスト併用ＨＩＶ療法
WO2005067963A1 (en) Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
WO2004105684A2 (en) Combination therapy for proliferative disorders
RU2392963C2 (ru) Синтетические варианты гипергликозилированного протеазо-резистентного полипептида, пероральные композиции и способы применения таких вариантов
WO2005062949A2 (en) Method for treating hepatitis virus infection
WO2005110478A2 (en) Combination therapy for treating fibrotic disorders
Taylor et al. IFN-α 1, 8 Inhibits Tumor-Induced Angiogenesis in Murine Angiosarcomas
WO2005110455A2 (en) Combination therapy for treating hepatitis virus infection
HK1136584A (en) Hyperglycosylated variants of interferon alfacon-1
CN101102787A (zh) 合成的超糖基化、抗蛋白酶的多肽变体、口服制剂及其使用方法
Shen The Challenges and Strategies of Biopharmaceutical Development and Global Management–PharmaEssentia
CN101516389A (zh) 用于治疗病毒感染的联合治疗
Pannu In vitro and in vivo antagonism of transforming growth factor-[beta] production by interferon-[alpha] 2b
Miller et al. Therapeutic for Hepatitis C

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070307

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid